Details of the Drug

General Information of Drug (ID: DMOPPXY)

• Drug Name: Camonsertib
• Synonyms: Camonsertib; RP-3500; RP3500; 2417489-10-0; camonsertib [INN]; Camonsertib [USAN]; Camonsertib (RP-3500); ATR inhibitor 4;Camonsertib; S1Z7Y5G56T; CHEMBL5095260; SCHEMBL23515008; SCHEMBL23515085; GTPL12073; RP 3500 [WHO-DD]; Rp 3500; 8-Oxabicyclo[3.2.1]octan-3-ol, 3-[6-[(3R)-3-methyl-4-morpholinyl]-1-(1H-pyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl]-, (3-endo)-; EX-A6416; NSC841442; NSC-841442; MS-27079; CS-0226170; F83116; (1R,3r,5S)-3-{6-[(3R)-3-methylmorpholin-4-yl]-1-(1Hpyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl}-8-oxabicyclo[3.2.1]octan-3-ol; (1R,3R,5S)-3-6-[(3R)-3-methylmorpholin-4-yl]-1-(1Hpyrazol-3-yl)-1H-pyrazolo[3,4-b]pyridin-4-yl-8-oxabicyclo[3.2.1]octan-3-ol; (1R,5S)-3-[6-[(3R)-3-methylmorpholin-4-yl]-1-(1H-pyrazol-5-yl)pyrazolo[3,4-b]pyridin-4-yl]-8-oxabicyclo[3.2.1]octan-3-ol

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 1/2	[1]

• Drug Type: Small molecule
• Chemical Identifiers:
  Formula: C21H26N6O3
  Canonical SMILES: CC1COCCN1C2=NC3=C(C=NN3C4=CC=NN4)C(=C2)C5(CC6CCC(C5)O6)O
  InChI: InChI=1S/C21H26N6O3/c1-13-12-29-7-6-26(13)19-8-17(21(28)9-14-2-3-15(10-21)30-14)16-11-23-27(20(16)24-19)18-4-5-22-25-18/h4-5,8,11,13-15,28H,2-3,6-7,9-10,12H2,1H3,(H,22,25)/t13-,14-,15+,21?/m1/s1
  InChIKey: YIHHYCIYAIVQKX-YNOVCBQDSA-N
• Cross-matching ID:
  PubChem CID: 156487652
  TTD ID: DDSW97

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Serine/threonine-protein kinase ATR (FRP1)	TT8ZYBQ	ATR_HUMAN	Inhibitor	[2]

References

• [1] ClinicalTrials.gov (NCT04972110) Phase 1b/2 Study of ATR InhibiTor RP-3500 and PARP Inhibitor Combinations in Patients With Molecularly Selected Cancers (ATTACC). U.S.National Institutes of Health.
• [2] Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results. Nat Med. 2023 Jun;29(6):1400-1411.